Back to Search
Start Over
Quad‐class exposed/refractory myeloma is associated with short survival.
- Source :
-
British Journal of Haematology . Jan2024, Vol. 204 Issue 1, p186-190. 5p. - Publication Year :
- 2024
-
Abstract
- Summary: Very scarce data exist about outcomes of relapsed multiple myeloma patients who have failed proteasome inhibitor, immunomodulatory drug, anti‐CD38 monoclonal antibody and therapies targeting B‐cell maturation antigen (BCMA) (Quad‐class exposed [QCE]). In this retrospective single‐centre study, we determined progression‐free survival (PFS) and overall survival (OS) from anti‐BCMA failure in 45 QCE patients. Seven (16%) patients received antibody‐drug conjugate, 20 (44%) bispecific antibodies and 18 (40%) CAR‐T cell. Thirty patients (67%) received ≥1 subsequent line of treatment. PFS was 4.4 months (95% CI = 2.4–12.5) and OS 6.3 months (95% CI = 3.9–14.4). Having an adverse prognosis, QCE myeloma patients remain an unmet medical need. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 204
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 174712876
- Full Text :
- https://doi.org/10.1111/bjh.19148